Login
Super Investors Fairmount Funds Management LLC
FF

Fairmount Funds Management LLC

Quarterly 13F snapshot: US-listed longs only, no performance figures — 13F data cannot support them.

Portfolio value
$1.59B
Positions
12
Quarter ended
September 30, 2026
Filed
November 16, 2026

Reported portfolio value by quarter (28 quarters reported)

$1.59B $165M
Q4 19 Q2 21 Q4 22 Q2 24 Q4 25 Q3 26

$165M in Q4 2019 → $1.59B now. Hover for any quarter.

Holdings

As reported for the quarter ended September 30, 2026. Activity is the change in share count since the prior quarter's filing.

Holding % of portfolio Activity Shares Value
Oruka Therapeutics Inc 19.4% Unchanged 3,705,262 $309M
Korsana Biosciences Inc 18.3% New 9,103,729 $291M
Dianthus Therapeutics Inc 14.0% Unchanged 2,537,191 $223M
Damora Therapeutics Inc 11.6% New 8,713,000 $185M
Cogent Biosciences Inc 11.1% Unchanged 5,503,418 $176M
VT Viridian Therapeutics Inc 6.6% Unchanged 5,090,928 $105M
Enliven Therapeutics Inc 5.3% Unchanged 1,855,644 $85.1M
Jade Biosciences Inc 4.0% Unchanged 4,553,494 $64M
Zenas Biopharma Inc 4.0% Added 0.5% 2,371,358 $64M
Crescent Biopharma Inc. 3.3% Added 31% 3,601,316 $52.5M
Faeth Therapeutics Inc 1.3% Unchanged 722,020 $21.5M
Inhibikase Therapeutics Inc 1.1% Unchanged 8,625,000 $17.7M

Timeline of changes

What changed each quarter, from the filings' own share counts. Largest moves first; most recent 8 quarters.

Q3 2026

quarter ended September 30, 2026 · filed November 16, 2026

Company Action Shares changed Value of change % of portfolio
Korsana Biosciences Inc New +9,103,729 +$291M 18.3%
Damora Therapeutics Inc Exited −8,713,000 −$227M —
Damora Therapeutics Inc New +8,713,000 +$185M 11.6%
Apogee Therapeutics Inc Exited −298,647 −$39.6M —
Crescent Biopharma Inc. Added +853,450 +$12.5M 3.3%
Zenas Biopharma Inc Added +12,333 +$333K 4.0%

Q2 2026

quarter ended June 30, 2026 · filed August 14, 2026

Company Action Shares changed Value of change % of portfolio
Spyre Therapeutics Inc Exited −4,018,101 −$203M —
VT Viridian Therapeutics Inc Added +1,176,470 +$21.6M 6.2%
Faeth Therapeutics Inc New +722,020 +$18.1M 1.2%

Q1 2026

quarter ended March 31, 2026 · filed May 15, 2026

Company Action Shares changed Value of change % of portfolio
Damora Therapeutics Inc New +8,713,000 +$226M 16.3%
Apogee Therapeutics Inc Trimmed −1,750,000 −$147M 1.8%
Cogent Biosciences Inc Trimmed −3,500,000 −$135M 15.3%
Nuvalent Inc Exited −727,563 −$73.2M —
Enliven Therapeutics Inc Trimmed −1,855,800 −$72.7M 5.3%
KP Kiniksa Pharmaceuticals Intl Exited −1,319,688 −$54.4M —
Dianthus Therapeutics Inc Added +400,000 +$33.6M 15.4%
Zenas Biopharma Inc Added +150,000 +$2.93M 3.3%

Q4 2025

quarter ended December 31, 2025 · filed February 17, 2026

Company Action Shares changed Value of change % of portfolio
Axsome Therapeutics Inc Exited −815,176 −$99M —
SR Scholar Rock Hldg Corp Exited −1,824,031 −$67.9M —
AS Abivax Sa Exited −713,434 −$60.6M —
Dianthus Therapeutics Inc Trimmed −1,170,000 −$48.2M 6.7%
Astria Therapeutics Inc Exited −3,554,129 −$25.9M —
Jade Biosciences Inc Added +1,333,126 +$20.6M 5.3%
KP Kiniksa Pharmaceuticals Intl Trimmed −453,151 −$18.7M 4.1%
Crescent Biopharma Inc. Added +1,360,000 +$16.1M 2.5%
VT Viridian Therapeutics Inc Added +454,545 +$14.1M 9.3%
Zenas Biopharma Inc Added +316,219 +$11.5M 6.1%

Showing the 10 largest of 11 changes.

Q3 2025

quarter ended September 30, 2025 · filed November 14, 2025

Company Action Shares changed Value of change % of portfolio
AS Abivax Sa New +713,434 +$60.6M 5.4%
Cogent Biosciences Inc Added +2,777,777 +$39.9M 11.6%
Dianthus Therapeutics Inc Added +600,000 +$23.6M 11.7%
Cytomx Therapeutics Inc Exited −3,896,582 −$8.85M —
Oruka Therapeutics Inc Added +333,340 +$6.41M 6.4%

Q2 2025

quarter ended June 30, 2025 · filed August 14, 2025

Company Action Shares changed Value of change % of portfolio
Jade Biosciences Inc New +3,220,368 +$32.2M 4.2%
Crescent Biopharma Inc. New +1,387,866 +$22.4M 2.9%
KP Kiniksa Pharmaceuticals Intl Added +670,591 +$18.6M 6.4%
SR Scholar Rock Hldg Corp Added +450,000 +$15.9M 8.4%
Bicara Therapeutics Inc Exited −784,170 −$10.2M —
Enliven Therapeutics Inc Added +508,646 +$10.2M 9.6%
Cytomx Therapeutics Inc New +3,896,582 +$8.85M 1.1%
VT Viridian Therapeutics Inc Added +14,100 +$197K 6.3%
Dianthus Therapeutics Inc Added +6,500 +$121K 6.5%

Q1 2025

quarter ended March 31, 2025 · filed May 15, 2025

Company Action Shares changed Value of change % of portfolio
Axsome Therapeutics Inc Trimmed −653,807 −$76.3M 14.7%
Nuvalent Inc Trimmed −590,101 −$41.8M 8.0%
Day One Biopharmaceuticals Inc Exited −3,103,448 −$39.3M —
KP Kiniksa Pharmaceuticals Intl Trimmed −1,092,093 −$24.3M 3.8%
Anaptysbio Inc Exited −1,816,466 −$24.1M —
SR Scholar Rock Hldg Corp Trimmed −588,922 −$18.9M 6.9%
Bicara Therapeutics Inc Trimmed −499,999 −$6.51M 1.6%

Q4 2024

quarter ended December 31, 2024 · filed February 14, 2025

Company Action Shares changed Value of change % of portfolio
SR Scholar Rock Hldg Corp New +1,962,953 +$84.8M 8.4%
Axsome Therapeutics Inc Trimmed −891,094 −$75.4M 12.4%
Nuvalent Inc Trimmed −369,400 −$28.9M 10.3%
Anaptysbio Inc New +1,816,466 +$24.1M 2.4%
KP Kiniksa Pharmaceuticals Intl Trimmed −1,010,500 −$20M 4.3%
Inhibikase Therapeutics Inc New +6,125,000 +$19.9M 2.0%
Oruka Therapeutics Inc Added +160,000 +$3.1M 6.5%
Bicycle Therapeutics PLC Exited −123,538 −$2.8M —

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support